Zhao Yi-Chang, Zou Yang, Hou Jing-Jing, Xiao Chen-Lin, Zhang Bi-Kui, Li Jia-Kai, Xiang Da-Xiong, Sandaradura Indy, Yan Miao
The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Institute of Pharmacy, Central South University, Changsha 410011, China.
Antibiotics (Basel). 2021 Dec 16;10(12):1542. doi: 10.3390/antibiotics10121542.
Voriconazole is a triazole antifungal agent commonly used for the treatment and prevention of invasive aspergillosis (IA). However, the study of voriconazole's use in children is limited. The present study was performed to explore maintenance dose to optimize voriconazole dosage in children and the factors affecting voriconazole trough concentration. This is a non-interventional retrospective clinical study conducted from 1 January 2016 to 31 December 2020. The study finally included 94 children with 145 voriconazole trough concentrations. The probability of achieving a targeted concentration of 1.0-5.5 µg/mL with empiric dosing increased from 43 (45.3%) to 78 (53.8%) after the TDM-guided adjustment. To achieve targeted concentration, the overall target maintenance dose for the age group of less than 2, 2 to 6, 6 to 12, and 12 to 18 years old was approximately 5.71, 6.67, 5.08 and 3.31 mg·kg-1/12 h, respectively ( < 0.001). Final multivariate analysis found that weight ( = 0.019), dose before sampling ( < 0.001), direct bilirubin ( < 0.001), urea nitrogen ( = 0.038) and phenotypes of CYP2C19 were influencing factors of voriconazole trough concentration. These factors can explain 36.2% of the variability in voriconazole trough concentration. Conclusion: In pediatric patients, voriconazole maintenance doses under the target concentration tend to be lower than the drug label recommended, but this still needs to be further studied. Age, body weight, dose, direct bilirubin, urea nitrogen and phenotypes of CYP2C19 were found to be influencing factors of voriconazole concentration in Chinese children. The influence of these factors should be taken into consideration during voriconazole use.
伏立康唑是一种三唑类抗真菌药物,常用于治疗和预防侵袭性曲霉病(IA)。然而,关于伏立康唑在儿童中应用的研究有限。本研究旨在探索维持剂量以优化儿童伏立康唑的给药剂量以及影响伏立康唑谷浓度的因素。这是一项于2016年1月1日至2020年12月31日进行的非干预性回顾性临床研究。该研究最终纳入了94名儿童,共获得145次伏立康唑谷浓度数据。在治疗药物监测(TDM)指导调整后,经验性给药达到1.0 - 5.5 µg/mL目标浓度的概率从43例(45.3%)增加到78例(53.8%)。为达到目标浓度,年龄小于2岁、2至6岁、6至12岁和12至18岁年龄组的总体目标维持剂量分别约为5.71、6.67、5.08和3.31 mg·kg-1/12 h(<0.001)。最终多因素分析发现,体重(=0.019)、采样前剂量(<0.001)、直接胆红素(<0.001)、尿素氮(=0.038)和CYP2C19表型是伏立康唑谷浓度的影响因素。这些因素可解释伏立康唑谷浓度变异性的36.2%。结论:在儿科患者中,低于目标浓度的伏立康唑维持剂量往往低于药品标签推荐剂量,但仍需进一步研究。发现年龄、体重、剂量、直接胆红素、尿素氮和CYP2C19表型是中国儿童伏立康唑浓度的影响因素。在使用伏立康唑时应考虑这些因素的影响。